Professor Thomas Powles

Professor Thomas Powles

MBBS, MRCP, MD
Centre: Experimental Cancer Medicine
Clinical Professor of Genitourinary Oncology (HCC)
This email address is being protected from spambots. You need JavaScript enabled to view it.

QMUL Directory


My main research interests are in genital and urinary cancers, leading a spectrum of clinical studies from phase I to randomised phase III.

Research Details

I am the lead for solid tumor research at Barts Cancer Institute. I also lead the genitourinary (GU) cancer group at BCI.

My work focuses on a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies.They exploit functional imaging and tissue collection.

Alongside these trials, our research focuses on correlation of novel biomarkers and aims to define markers that are of prognostic value and can predict response or resistance to therapy.

I have written over 100 peer review papers in this area and have grant income from national and international funding bodies.

I am on the editorial board of a number of journals and am part of the faculty for the major global oncology meetings.

Profile

I qualified from St Bartholomew’s Medical School in 1996 and trained in medical oncology at Imperial College. I completed post-graduate training in oncology in 2005 and received an MD from the University of London in 2006. My thesis was in mechanisms of resistance to therapy in urology cancers.

Funding

2013

Millenium Pharmaceuticals Inc

“NEPTUNE study of neoadjuvant TAK-700 and leuprorelin acetate versus surgery alone in intermediate and high risk clinically localized disease”
£979,682

2012

Barts And The London Charity

“The Identification of predictive biomarkers to targeted therapy in urological cancers”
£46,917

2012

NHS National Services Scotland

Lab Services – Orchid
£5,000

2012

AstraZeneca UK Limited

“ZEBRA Comparing AZD2014 and Everolimus”
£243,999

2012

AstraZeneca UK Limited

Re-Imbursement Everolimus
£906,000

2012

Dendreon Corporation

“An open-label study of sipuleucel-t in European men with metastatic, castrate resistant prostate cancer”
£69,041

2011

Pfizer Ltd

“Identification of molecular markers associated with response and resistance to sunitinib”
£47,000

2011

Barts Health NHS Trust

Lamb Study - Contingency Support

2010

Medical Research Council

£73,630

2010

GlaxoSmithKline Research & Development

“A Phase II Study Investigating Upfront Pazopanib In Metastatic Clear Cell Renal Cancer (Panther).”
£1,155,763

2010

Novartis Pharmaceuticals Uk Ltd

“Study of dovitinib and everolimus in clear cell renal cancer resistant to VEGF targeted therapy”
£17,200

2010

Novartis Pharmaceuticals Uk Ltd

(As above)
£192,800

2010

Medical Research Council

Industrial Case Studentship – 2010
£63,554

2010

AstraZeneca UK Limited

Industrial Case Studentship – 2010
£12,000

2008

GlaxoSmithKline Services Unlimited

LaMB Study
£263,854

2008

Central & Eastern CLRN

CLRN-LaMB Study
£85,589

2008

Barts Health NHS Trust

LaMB Study

Key Publications

T Powles, JP Eder, GD Fine, FS Braitch, Y Loriot, C Cruz, J Bellmunt, HA Burris, DP Petrylak, SM Teng, X Shen, Z Boyd, PS Hegde, DS Chen, NJ Vogelzang. MPDL3280A (Anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014. PMID: 25428503

Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin K, Lotz JP, Germà-Lluch JR, Powles T, Kollmannsberger C, Beyer. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011. PMID: 21444870

Katani I, Avril NE, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P, Shamash J, Sharpe K, Lim L, Dickson J, Ell P, Reynolds AR, Powles T. Sequential FDG-PET/CT as a biomarker of response to sunitinib in metastatic clear cell renal cancer. Clin Cancer Res. 2011. PMID: 21742806

Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Møller H, Bower M. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection .J Clin Oncol. 2009. PMID: 19114688


Further Publications

For additional publications, please click here.


My main research interests are in genital and urinary cancers, leading a spectrum of clinical studies from phase I to randomised phase III.

External Activities

  • NCRN bladder cancer CSG
  • NCRN renal cancer CSG
  • NCRN translational oncology group
  • NCRN CRPC studies group.
  • EORTC-GU executive committee
  • ESMO faculty for GU cancer.
  • Editorial board of Clinical Genitourinary Cancer
  • Co chair of trans Atlantic bladder cancer consortium
  • International guidelines for testis cancer and renal cancer

News

  • November 2014: publication of bladder cancer clinical trial in Nature with media coverage
  • December 2013: Kidney cancer drug trial set up with CRUK, Cancer Research Technology and AstraZeneca
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.